Departmental Affiliation and City, State, Zip for All Authors

UNT Health Science Center North Texas Eye Research Institute Fort Worth,Texas ,76107

Scientific Abstract

Glaucoma is a group of diseases closely associated with vision loss due to conditions such as elevated intraocular pressure (IOP) and degeneration of retinal ganglion cells (RGCs). RGCs are vital to vision because they are responsible for sending visual information to the brain. Studies show that B crystallin can be used to prevent this degeneration in RGCs therefore impeding further neurodegenerative in glaucoma. The main goal of this experiment is to test the neuroprotective effects of the B crystallin core peptide (ABCP) on isolated primary RGCs as well as whole retinal explants in glaucomatous (hypoxic) conditions. Both postnatal day 7 primary RGCs and adult retinal explants were exposed to either normoxic or hypoxic conditions and treated with ABCP (12.5 g/mL) or scrambled peptide (12.5 g/mL). Survival of primary RGCs was examined using Blue/Red cell viability reagent(ENZ-53005) allowing to detect live and dead cells while retinal explants were stained with Brn3a antibody (RGC marker) to count surviving cells. The hypoxic conditions proved to be harmful to the RGCs and caused cell degeneration. When exposed to hypoxia, the ABCP peptide showed neuroprotective properties for both the primary RGCs and adult retinal explants. The conclusion from our study was that ABCP can be potentially used as a therapy in glaucoma. Funded by the Department of Health and Human Services, National Institute of Health, National Heart, Lung and Blood Institute, SMART Grant 5R25HL007786-25 to Dr. Jamboor K. Vishwanatha, Ph.D. Keywords: • B crystallin core peptide(ABCP) • Scrambled peptide • Primary Retinal Ganglion Cells (RGCs) • Retinal explants • Hypoxia • Normoxia

Share

COinS
 

Neuroprotective properties of aB-Crystallin core peptide

Glaucoma is a group of diseases closely associated with vision loss due to conditions such as elevated intraocular pressure (IOP) and degeneration of retinal ganglion cells (RGCs). RGCs are vital to vision because they are responsible for sending visual information to the brain. Studies show that B crystallin can be used to prevent this degeneration in RGCs therefore impeding further neurodegenerative in glaucoma. The main goal of this experiment is to test the neuroprotective effects of the B crystallin core peptide (ABCP) on isolated primary RGCs as well as whole retinal explants in glaucomatous (hypoxic) conditions. Both postnatal day 7 primary RGCs and adult retinal explants were exposed to either normoxic or hypoxic conditions and treated with ABCP (12.5 g/mL) or scrambled peptide (12.5 g/mL). Survival of primary RGCs was examined using Blue/Red cell viability reagent(ENZ-53005) allowing to detect live and dead cells while retinal explants were stained with Brn3a antibody (RGC marker) to count surviving cells. The hypoxic conditions proved to be harmful to the RGCs and caused cell degeneration. When exposed to hypoxia, the ABCP peptide showed neuroprotective properties for both the primary RGCs and adult retinal explants. The conclusion from our study was that ABCP can be potentially used as a therapy in glaucoma. Funded by the Department of Health and Human Services, National Institute of Health, National Heart, Lung and Blood Institute, SMART Grant 5R25HL007786-25 to Dr. Jamboor K. Vishwanatha, Ph.D. Keywords: • B crystallin core peptide(ABCP) • Scrambled peptide • Primary Retinal Ganglion Cells (RGCs) • Retinal explants • Hypoxia • Normoxia

Manuscript Number

1005